1De Silvestro G, Marson P, Brandolese R,et al. A single institution's experience(1992-1999) with plasma-exchange therapy in patients with fulminant hepatic failure. Int J Artif Organ,2000,23:454.
2Kondrup J, Almadal T, Vilstrup H, et al. High volume plasma exchange in fulminant hepatic failure. Int J Artif Organs, 1992,15(11):669-675.
3Sadahiro T, Hirasawa H, Oda S, et al. Usefulness of plasma exchange plus continuous hemodiafiltration to reduce adverse effects associated with plasma exchange in patients with acute liver failure Crit Care Med,2001,29(7): 1386-1392.
4Nakae H, Yonekawa T, Narita K, et al. Are proinflammatory cytokine concentrations reduced by plasma exchange in patients with severe acute hepatic failure? Res Commun Mol Pathol Pharmacol, 2001,109(1-2):65-72.
5Takahashi Y. Evaluation of the special therapies in fulminant viral hepatitis- a multi-institution study. Nippon Shokakibyo Gakkai Zasshi,1995,92(1) :7-18.
6Kramer P, Wegger W, Rieger J,et al. Arteriovenous hemofiltration: a new and simple method for treatment of over hydrated patients resistant to diuretics. Klin Wochenschr, 1977,55:1121.
7Bellomo R, Ronco C. Blood purification in the intensive care unit: evolving concepts. World J Surg,2001,25(5) :677-683.
8Iwamura Y,Yoshiba M,Sugata F. Treatment of fulminant hepatitis with highly reliable artificial liver support and administration of interferon.Nippon Shokakibyo Gakkai Zasshi, 1990,87(1): 109-118.
9Yoshiba M, Sekiyama K, Iwamura Y, et al. Development of reliable artificial liver support (ALS)-plasma exchange in combination with hemodialiltration using high-performance membranes. Dig Dis Sci, 1993, 38(3) :469-476.
10Yoshiba M, Inoue K, Sekiyama K, et al. Favorable effect of new artificial liver support on survival of patients with fulminant hepatic failure. Artif Organs, 1996,20( 11 ): 1169-1172.
